Apogee Therapeutics, Inc.APGENASDAQ
Loading
| Metric | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 |
|---|---|---|---|---|---|
| Revenue Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Gross Profit Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| EBITDA Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Operating Income Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Net Income Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| EPS Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| EPS Diluted Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Weighted Average Shares Growth | +8.96% | +15.95% | +3.39% | +3.48% | +9.96% |
| Weighted Average Shares Diluted Growth | +8.96% | +15.95% | +3.39% | +3.48% | +9.96% |
| Dividends per Share Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Operating Cash Flow Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Free Cash Flow Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Receivables Growth | +286.90% | +0.00% | +0.00% | -6.16% | -100.00% |
| Inventory Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Asset Growth | +87.83% | -13.29% | -17.85% | -19.34% | +24.30% |
| Book Value per Share Growth | +73.16% | -27.54% | -22.56% | -22.85% | +14.68% |
| Debt Growth | +481.66% | +567.19% | +165.61% | -18.84% | -25.20% |
| R&D Expense Growth | +108.02% | +61.54% | +67.75% | +18.52% | -2.96% |
| SG&A Expenses Growth | +90.85% | +75.02% | +56.99% | +31.82% | +28.29% |